Prospective clinical study of CCCG-RMS-2016 protocol for children and adolescents with rhabdomyosarcoma

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800019434

Enrollment

Unknown

Registered

2018-11-11

Start date

2018-12-01

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhabdomyosarcoma

Interventions

Case series:CCCG-RMS-2016 protocol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly diagnosed rhabdomyosarcoma patients under 18 years old, without severe organ dysfunction

Exclusion criteria

Exclusion criteria: 1. Disease progression; 2. Organ dysfunction do not recover after 35 days from the last chemotherapy; 3. Patients or their parents do not agree to continue using this protocol; 4. Treatment completed.

Design outcomes

Primary

Measure	Time frame
response rate;	—

Secondary

Measure	Time frame
the rate of unaccepted side-effect;1 year survival rate;	—

Countries

China

Contacts

Public ContactXiaoli Ma

Capital Medical University, Beijing Children's Hospital

mxl1123@vip.sina.com+86 13370115038

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026